What would any day be without word of a Johnson & Johnson product being recalled? In this instance, the Animas unit, which sells products for treating diabetes, has recalled a batch of 45,000 faulty insulin cartridges that were shipped between last November and early January because the items may leak insulin. You can read the letter here.

Normally, many would consider such recalls to be run-of-the-mill actions that do not merit much, if any, attention. However, as you know, Johnson & Johnson is under a microscope because of its handling of serious manufacturing difficulties that have led to the recalls of tens of millions of products, from over-the-counter meds and syringes to contact lenses and hip replacement devices.

The string of recalls has led to job losses, loss of investor confidence, $900 million in lost sales last year, congressional investigations, regulatory scrutiny and eroding consumer trust. There have also been calls for the J&J board to terminate ceo Bill Weldon. While his bonus was cut, the board, nonetheless, offered a token raise of $60,000 (read here).

The Animus recall, by the way, was first reported by Diabetes Mine, which alerted us to the move. And so, we extend a belated hat tip.